This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 945-946, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Antipneumococcal Activities of a Ketolide (HMR 3647), a Streptogramin (Quinupristin-Dalfopristin), a Macrolide (Erythromycin), and a Lincosamide (Clindamycin)

A. L. Barry,* P. C. Fuchs, and S. D. Brown

The Clinical Microbiology Institute, Wilsonville, Oregon 97070

Received 4 August 1997/Returned for modification 17 December 1997/Accepted 18 January 1998

Four different compounds belonging to the macrolide-lincosamide-streptogramin B (MLSb) class of antimicrobial agents were tested against 611 Streptococcus pneumoniae strains. The ketolide (HMR 3647, previously RU66647) and the streptogramin (quinupristin-dalfopristin) were both active against pneumococci with high-level MLSb resistance (clindamycin-resistant strains) as well as those with low-level macrolide resistance (clindamycin-susceptible strains).

* Corresponding author. Mailing address: The Clinical Microbiology Institute, 9725 S.W. Commerce Circle, Suite A-1, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-2065. E-mail: cmi{at}hevanet.com.

Antimicrobial Agents and Chemotherapy, April 1998, p. 945-946, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fogarty, C., de Wet, R., Mandell, L., Chang, J., Rangaraju, M., Nusrat, R. (2005). Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization. Chest 128: 1980-1988 [Abstract] [Full Text]  
  • Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 49: 188-194 [Abstract] [Full Text]  
  • Shi, J., Montay, G., Chapel, S., Hardy, P., Barrett, J. S., Sack, M., Marbury, T., Swan, S. K., Vargas, R., Leclerc, V., Leroy, B., Bhargava, V. O. (2004). Pharmacokinetics and Safety of the Ketolide Telithromycin in Patients with Renal Impairment. J Clin Pharmacol 44: 234-244 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G. (2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y., Tyrrel, K. L., Fernandez, H. (2003). In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis. Antimicrob. Agents Chemother. 47: 1963-1967 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Maurin, M., Bryskier, A., Raoult, D. (2002). Antibiotic Susceptibilities of Parachlamydia acanthamoeba in Amoebae. Antimicrob. Agents Chemother. 46: 3065-3067 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Fuchs, P. C., Barry, A. L., Brown, S. D. (2002). In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime. J Antimicrob Chemother 49: 399-401 [Abstract] [Full Text]  
  • Muller-Serieys, C., Soler, P., Cantalloube, C., Lemaitre, F., Gia, H. P., Brunner, F., Andremont, A. (2001). Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647). Antimicrob. Agents Chemother. 45: 3104-3108 [Abstract] [Full Text]  
  • Barry, A. L., Fuchs, P. C., Brown, S. D. (2001). In Vitro Activity of the Ketolide ABT-773. Antimicrob. Agents Chemother. 45: 2922-2924 [Abstract] [Full Text]  
  • Odenholt, I., Löwdin, E., Cars, O. (2001). Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract Pathogens. Antimicrob. Agents Chemother. 45: 23-29 [Abstract] [Full Text]  
  • Piroth, L., Desbiolles, N., Mateo-Ponce, V., Martin, L., Lequeu, C., Charles, P.-E., Portier, H., Chavanet, P. (2001). HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 33-42 [Abstract] [Full Text]  
  • Namour, F., Wessels, D. H., Pascual, M. H., Reynolds, D., Sultan, E., Lenfant, B. (2001). Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses. Antimicrob. Agents Chemother. 45: 170-175 [Abstract] [Full Text]  
  • Yamaguchi, T., Hirakata, Y., Izumikawa, K., Miyazaki, Y., Maesaki, S., Tomono, K., Yamada, Y., Kamihira, S., Kohno, S. (2000). In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan. Antimicrob. Agents Chemother. 44: 1381-1382 [Abstract] [Full Text]  
  • Davies, T. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2000). In Vitro Development of Resistance to Telithromycin (HMR 3647), Four Macrolides, Clindamycin, and Pristinamycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 414-417 [Abstract] [Full Text]  
  • Descheemaeker, P., Chapelle, S., Lammens, C., Hauchecorne, M., Wijdooghe, M., Vandamme, P., Ieven, M., Goossens, H. (2000). Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 45: 167-173 [Abstract] [Full Text]  
  • Barry, A. L., Fuchs, P. C., Brown, S. D. (1998). In Vitro Activities of the Ketolide HMR 3647 against Recent Gram-Positive Clinical Isolates and Haemophilus influenzae. Antimicrob. Agents Chemother. 42: 2138-2140 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»